地诺单抗用于骨转移癌治疗的研究

癌症转移是致死的主要原因，骨是排第三的好发转移部位。OPG／RANKL—RANK骨调节轴是影响破骨细胞发育及功能的唯一途径。地诺单抗（denosumab）是全人源化结合RANKL的中和抗体，由FDA于2010年11月批准用于实体瘤骨转移的治疗。本文就地诺单抗用于骨转移癌治疗的机制及临床实验研究作一综述，为临床医生更合理的选择骨改构药物用于骨转移癌的治疗做指导。

The study about denosumab on bone metastasis of cancer

Cancer is a major public health problem in the world. Metastasis is the principal cause of morbidity and death of cancer patients. Bone is the third most common site of cancer metastasis. Previous studies have shown that RANKL signaling has been implicated in many bone diseases to increase bone resorption and tumor cells use the RANKL- RANK axis to induce the differentiation of the precursors into osteoclasts and lead to osteolysis. The US Food and Drug Administration has authorized of Denosumab, a fully human monoclonal antibody to RANKL,which blocks binding of RANKL to RANK in November 2010 to reduce the development of SREs in patients with bone metastases in the setting of a solid tumor. We will explore the mechanism and summary the clinical trials of denosumab on bone metastasis of cancer in order to help clinician selecting correctly bone modified drug （BMD） to treat bone metastasis.